Abstract 1916P
Background
Dual ICI therapy is the standard of care for first-line PM patients (pts); single agent ICI improved survival vs placebo in pretreated pts. However, ICI efficacy is comprehensively unsatisfactory in PM, and no biomarkers predict response to therapy. We aimed to identify tumor features correlated with ICI efficacy in PM pts.
Methods
The NIBIT-EPI-MESO is a multicenter study led by the NIBIT Foundation in ICI-treated PM pts. Pts with irPR or irSD were classified as responders (R), those with irPD as non-responders (NR). Tumor biopsies underwent multi-omics analyses: RNA-seq, WES, RRBS, and multiplex immunofluorescence (mIF). Results were correlated with clinical outcome.
Results
Among 73 pts studied 54 had epithelioid, 16 biphasic, and 3 sarcomatoid PM; 64 received ICI as second/third line: 27 tremelimumab plus durvalumab (Calabrò, TLRM 2018), 36 nivolumab plus ipilimumab (Italian expanded access), 10 tremelimumab monotherapy (Calabrò, TLRM 2015). IrPR, irSD, and irPD were achieved by 27%, 36% and 37% of pts. Methylation profiling clustered pts into four subtypes: Demethylated, Low, Intermediate, and CIMP (hypermethylated). The Low cluster was enriched in R pts (22/41; p=0.01) who had the highest mOS (970 days), whereas the CIMP cluster was enriched in NR pts who had the worst mOS (288 days). Also, the Low cluster was the most predictive of ICI outcome in a multivariate model including sex, age, TMB, INFg gene expression (HR=0.1, CI: 0.02-0.47; p=0.003). An enriched proliferation and mitochondrial metabolism characterized the CIMP cluster, while the Low cluster was enriched in pathways associated with innate/adaptive immune response. The Low cluster had higher densities of tumor-associated CD8+ T (p=0.032) and CD20+ B cells (p=0.01) by mIF, compared to CIMP tumors. Tumor and stroma CD20+ B cells associated with response (p=0.016 and p=0.043), tumor CD4+ (p=0.009), CD8+ (p=0.01), CD68+(p=0.017) associated with OS. The low mutational rate identified did not associate with ICI response or OS.
Conclusions
Tumor methylation drives efficacy of ICI therapy in PM pts by shaping tumor immune contextures, regardless of PM histology and TMB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AIRC Foundation (ID.21073); Ministry of Health, Lombardy and Tuscany regions (NET-2016-02361632).
Disclosure
L. Calabro: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Roche, Merck Sharp Dohme; Financial Interests, Personal, Financially compensated role: Bristol Myers Squibb, AstraZeneca, Sanofi. F.P. Caruso, T. Noviello: Other, Personal, Stocks/Shares: Immunomics. A. Covre, S. Coral: Other, Personal, Stocks/Shares: Epigen Therapeutics. F. Grosso: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Novocure, Novartis, Pierre Fabre, Merck Sharp Dohme, PharmaMar. A.M. Di Giacomo: Financial Interests, Personal, Advisory Board: Pierre Fabre, GSK, Bristol Myers Squibb, Merck Sharp Dohme, Sunpharma, Immunocore, Sanofi; Financial Interests, Personal, Financially compensated role: Bristol Myers Squibb, Merck Sharp Dohme, Pierre Fabre, Sanofi. M. Ceccarelli: Other, Personal, Stocks/Shares: Immunomics; Financial Interests, Personal, Speaker, Consultant, Advisor: Moderna Therapeutics. M. Maio: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Pierre Fabre, Merck Serono, Amgen, Eli Lilly, Roche, Merck Sharp Dohme, Incyte, AstraZeneca, GSK, Sciclone, Sanofi, Alfasigma; Other, Personal, Stocks/Shares: Epigen Therapeutics, Theravance. All other authors have declared no conflicts of interest.
Resources from the same session
1936P - Treatment outcomes of patients with anaplastic thyroid carcinoma (atc): Multicentric data from spanish national registry (regetne-tiroides)
Presenter: José Miguel Rodellar
Session: Poster session 18
1937P - Clinical characteristics and prognosis of pediatric patients with papillary thyroid carcinoma
Presenter: Junko Akaishi
Session: Poster session 18
1938P - Nomogram for predicting lung metastases in patients with papillary thyroid cancer under 55 years old
Presenter: Huiyun Yang
Session: Poster session 18
1939P - BrafV600E-induced cancer inflammation in a mouse model of thyroid tumorigenesis
Presenter: Sima Kumari
Session: Poster session 18
1940TiP - Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design
Presenter: Alejandro Garcia Alvarez
Session: Poster session 18
1941TiP - Neoadjuvant pembrolizumab in high-risk thyroid cancer (NePenTHe)
Presenter: Claudia Leli
Session: Poster session 18
1924P - Efficacy and safety of lenvatinib in patients with chemotherapy-naive advanced or recurrent thymic carcinoma: A multicenter retrospective study
Presenter: Daisuke Hazama
Session: Poster session 18
1923P - Real-world management and outcome of thymic carcinomas in a tertiary German center
Presenter: Antonia Margineanu
Session: Poster session 18
1922P - Targeted resequencing designed specifically for thymic epithelial tumours confirmed the high prevalence of GTF2I mutations
Presenter: Iacopo Petrini
Session: Poster session 18
1921P - Molecular analysis of mesothelioma reveals mutations as prognostic biomarkers for patients treated with the combination of ipilimumab and nivolumab
Presenter: Angelica Rigutto
Session: Poster session 18